This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either Bevacizumab or Anlotinib.
Age ≥18 years;
Histopathologically confirmed diagnosis of lung cancer;
Receiving Bevacizumab or Anlotinib treatment;
Positive urine protein detection, with 0.15g < 24-hour urinary protein quantification < 3.5g;
Known allergy, contraindication, or caution to any component of Huaier Granules;
Inability to take oral medication;
Required or ongoing use of drugs known to potentially affect proteinuria, including but not limited to ACE inhibitors, glucocorticoids (>3 weeks), and Chinese patent medicines (as per respective drug prescribing information);
Proteinuria caused by underlying diseases, including but not limited to nephropathy, hypertension, urinary tract infection, systemic lupus erythematosus, multiple myeloma, etc.;